Twinrix (Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

TWINRIX drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

CONTRAINDICATIONS

Hypersensitivity to any component of the vaccine, including yeast and neomycin, is a contraindication (see DESCRIPTION). This vaccine is contraindicated in patients with previous hypersensitivity to TWINRIX or monovalent hepatitis A or hepatitis B vaccines.

REFERENCES

1. Day SP, Lemon SM. Hepatitis A virus. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia, PA: WB Saunders Company; 1992:1787-1791.
2. Dienstag JL, Routenberg JA, Purcell RH, et al. Foodhandler-associated outbreak of hepatitis type A. An immune electron microscopic study. Ann Intern Med 1975;83:647-650.
3. Mackowiak PA, Caraway CT, Portnoy BL. Oyster-associated hepatitis: Lessons from the Louisiana experience. Am J Epidemiol 1976;103(2):181-191.
4. Woodson RD, Clinton JJ. Hepatitis prophylaxis abroad. Effectiveness of immune serum globulin in protecting Peace Corps volunteers. JAMA 1969;209(7):1053-1058.
5. Krugman S, Giles JP. Viral hepatitis. New light on an old disease. JAMA 1970;212(6):1019-1029.
6. Hadler SC, Erben JJ, Francis DP, et al. Risk factors for hepatitis A in day-care centers. J Infect Dis 1982;145(2):255-261.
7. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease. Baltimore, MD: Williams & Wilkins; 1991:14-20.
8. Centers for Disease Control and Prevention. Summary of Notifiable Diseases, United States. 1996. MMWR 1997;45(53):73.
9. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48 (No. RR-12):1-31.
10. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med 1985;313(17):1059-1067.
11. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-226.
12. Centers for Disease Control and Prevention. Atkinson W, Wolf C, Humiston S, Nelson R (eds). Epidemiology and prevention of vaccine-preventable diseases. 6th ed. Atlanta, GA: Public Health Foundation: 2000:191-229.
13. Chiriaco P, Guadalupi C, Armigliato M, et al. Polyphasic course of hepatitis type A in children. J Infect Dis 1986; 153(2):378-379.
14. Data on file (TWR101), GlaxoSmithKline.
15. Koff RS. Hepatitis B and hepatitis D. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia, PA: WB Saunders Company; 1992:709-716.
16. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: Final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983;3(2):135-141.
17. Chang MH, Chen CJ, Lai MS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336(26):1855-1859.
18. Lee MS, Kim DH, Kim H, et al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea. Int J Epidemiol 1998;27:316-319.
19. Frisch-Niggemeyer W, Ambrosch F, Hofmann H. The assessment of immunity against hepatitis B after vaccination. J Bio Stand 1986;14(3):255-258.
20. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1999;47 (RR-1):99-104.
21. Centers for Disease Control and Prevention. Hepatitis surveillance report No. 57. Atlanta, GA:DHHS; 2000:12.
22. Centers for Disease Control and Prevention. Health information for international travel, 1999-2000. Atlanta, GA: DHHS.
23. Ascherio A, Zhang SM, Hern[aacute]n MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344(5):327-332.
24. Confavreux C, Suissa S, Saddier P, et al. Vaccination and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344(5):319-326.
25. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins for persons with altered immunocompetence. MMWR 1993;42 (RR-4):1-18.
26. Centers for Disease Control and Prevention. Vaccine adverse event reporting system--United States. MMWR 1990;39(41):730-733.
27. Data on file (TWR201), GlaxoSmithKline.
28. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(RR-1):23.

Manufactured by GlaxoSmithKline,

Rixensart, Belgium, US License No. 1617

Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709

TWINRIX, HAVRIX, ENGERIX-B, and TIP-LOK are registered trademarks of GlaxoSmithKline. ENZYMUN-TEST is a registered trademark of Boehringer Mannheim Immunodiagnostics. AUSAB is a registered trademark of Abbott Laboratories.

©2003, GlaxoSmithKline. All rights reserved.

August 2003/TW:L5